Kim John Sunshin 4
Research Summary
AI-generated summary
Cognizant (CTSH) CLO Kim Sunshin Receives Equity Awards
What Happened
Kim John Sunshin, Cognizant’s Chief Legal Officer, Chief Administrative Officer and Corporate Secretary, received equity awards on February 25, 2026. The filing shows three derivative grants: 26,903 restricted stock units (RSUs), 3,261 RSUs, and 10,972 performance-based stock units (PSUs). The grants are recorded at $0.00 per share (awards, not purchases or sales). The PSUs represent an allocated portion (~57%) of a 19,166 PSU award from 2023 and are scheduled to vest/settle on March 15, 2026 subject to continued service and achievement of performance criteria.
Key Details
- Transaction date and price: February 25, 2026; grant/acquisition code A; reported price $0.00 (derivative awards).
- Award schedules:
- 26,903 RSUs vest in 12 quarterly installments beginning June 1, 2026 and fully vest March 1, 2029.
- 3,261 RSUs vest over quarterly installments with a staggered schedule beginning June 1, 2026 and completing March 1, 2029 (varied fractions per quarter).
- 10,972 PSUs are a portion of a March 6, 2023 PSU grant for which ~57% of performance criteria were met; these will vest and settle in shares on March 15, 2026 if employment continues.
- Shares owned after transaction: not disclosed in the provided excerpt.
- Filing: Form 4 filed Feb 27, 2026 for transactions dated Feb 25, 2026 — appears timely (Form 4 is generally due within two business days).
- Transaction code meaning: A = Award/Grant; RSUs/PSUs are contingent rights to receive shares, not immediate open-market purchases.
Context
- RSUs and PSUs are compensation/retention awards and represent future contingent issuance of common stock if vesting and performance conditions are met; they do not represent a cash outlay by the insider at grant.
- The PSU portion here reflects performance measurement from a prior grant (2023); settlement is conditional on both committee determination and continued service through the settlement date.
- Such grants are routine executive compensation and should be interpreted differently than open-market purchases or sales.